Vactosertib and Durvalumab in Gastric Cancer

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hark Kyun Kim
• Treatments: Durvalumab

Criteria

Inclusion Criteria:

• Have histologically- or cytologically-confirmed diagnosis of metastatic gastric adenocarcinoma in the stomach and gastroesophageal junction that are refractory to at least two lines of treatment.

• Have a performance status of 0-1 on the ECOG Performance Scale.

• Have measurable disease at least one investigator-assessed measurable disease per RECIST v1.1

• Have adequate organ functions

Exclusion Criteria:

• Prior ALK5 inhibitor treatment

• Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs

• Patients weighing <30kg